Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the approach.

Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.